Recent Company News

• 06:00 AM ET Dec 05, 2025
  

  FDA approves clinical trials of CSPC Pharmaceutical Group's SYH2069 injection for weight management (HK$7.71, 0.00)

• 05:35 AM ET Dec 03, 2025
  

  FDA approves US trials of CSPC Pharmaceutical Group's SYH2056 for major depressive disorder (HK$7.70, 0.00)

• 03:54 AM ET Dec 02, 2025
  

  StreetAccount Sector Summary - China Healthcare November Recap

• 05:25 AM ET Nov 26, 2025
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval for JMT206 for weight management (HK$7.95, 0.00)

• 10:14 PM ET Nov 20, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:23 AM ET Nov 24, 2025
  

  CSPC Pharmaceutical Group receives FDA approval for clinical trials of SYH2061 injection (HK$7.56, 0.00)

• 09:12 AM ET Nov 21, 2025
  

  NMPA approves clinical trial of CSPC Pharmaceutical Group's SYH2056 tablets for depressive disorders (HK$7.38, 0.00)

• 11:32 PM ET Nov 20, 2025
  

  CSPC Pharmaceutical Group downgraded to hold from buy at UOB Kay Hian Securities (HK$7.38, -0.34)